Want to see SLGL full AI Analyst Report?
SLGL Stock Chart & Stats
$81.96
-$2.13(-2.60%)
At close: 4:00 PM EDT
$81.96
-$2.13(-2.60%)
Day’s Range― - ―
52-Week Range$11.82 - $97.97
Previous Close$79.83
Volume47.21K
Average Volume (3M)34.17K
Market Cap
$268.87M
Enterprise Value$172.77
Total Cash (Recent Filing)$30.47M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
May 07, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding3,268,991
10 Day Avg. Volume44,977
30 Day Avg. Volume34,168
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)5.15
Price to Sales (P/S)6.06
P/FCF Ratio426.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$193.00Price Target Upside135.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-9.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intellectual Property ExtensionExtending method-of-use patent protection for SGT-610 to 2044 materially lengthens exclusivity for the lead asset. This durable IP protection supports long-term commercial upside, enhances licensing and royalty potential, and raises barriers to generic competition over the drug's commercialization window.
Revenue Recovery And Product EconomicsA strong 2025 top-line rebound with gross profit nearly matching revenue indicates healthy product-level economics and improving market traction. If sustained, this trend can generate recurring cash flow, enable operational leverage, and support reinvestment without sole dependence on external financing.
Low Leverage And Extended Cash RunwayVery low debt keeps financial flexibility high, and the $33.1M capital raise meaningfully extends runway. Together these reduce near‑term refinancing risk, allow funding of pivotal trials and commercialization, and provide time to convert improving operations into sustainable cash generation.
Bears Say
Ongoing Net Losses And Eroding EquityCumulative losses have materially eroded the equity base, reducing the balance-sheet cushion to absorb setbacks. Persistent net losses constrain the company's ability to self‑fund growth or absorb adverse outcomes, increasing dependence on capital markets or partnerships for durable operations.
Historic Cash Burn And Funding RiskWhile 2025 returned modest positive operating and free cash flow, the company has a recent multi-year history of heavy cash burn. That legacy creates funding risk: if improved cash generation proves temporary, management may need dilutive raises or cut investment, which would impede long-term growth plans.
Profitability And Margin VolatilityLarge, volatile swings in margins and recurring operating losses reduce predictability of future earnings and cash flow. Such instability complicates budget planning, makes long-term operating leverage uncertain, and raises execution risk for commercial scaling or funding of late‑stage clinical programs.
Sol-Gel Technologies News
SLGL FAQ
What was Sol-Gel Technologies’s price range in the past 12 months?
Sol-Gel Technologies lowest stock price was $11.82 and its highest was $97.97 in the past 12 months.
What is Sol-Gel Technologies’s market cap?
Sol-Gel Technologies’s market cap is $268.87M.
When is Sol-Gel Technologies’s upcoming earnings report date?
Sol-Gel Technologies’s upcoming earnings report date is May 07, 2027 which is in 277 days.
How were Sol-Gel Technologies’s earnings last quarter?
Currently, no data Available
Is Sol-Gel Technologies overvalued?
According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued.
Does Sol-Gel Technologies pay dividends?
Sol-Gel Technologies does not currently pay dividends.
What is Sol-Gel Technologies’s EPS estimate?
Sol-Gel Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sol-Gel Technologies have?
Sol-Gel Technologies has 3,268,991 shares outstanding.
What happened to Sol-Gel Technologies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sol-Gel Technologies?
Currently, no hedge funds are holding shares in SLGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sol-Gel Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$193.00 (135.48% Upside)
$193.00 (135.48% Upside)
Blogger Sentiment
Bullish
SLGL Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $494.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 26.7%
Last 30 Days ▲ 26.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
637.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
116.35%
Trailing 12-Months
Company Description
Sol-Gel Technologies
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
SLGL Stock 12 Month Forecast
Average Price Target
$193.00
▲(135.48% Upside)
Technical Analysis
Insight Molecular Diagnostics
―
Ovid Therapeutics
―
Shattuck Labs
―
Surrozen
―
Metagenomi, Inc.
―
Ownership Overview
15.52% Insiders
0.04% Mutual Funds
36.17% Other Institutional Investors
47.36% Public Companies and
Individual Investors